Bertol, Bruna Cristina 
; Bales, Elise S.; Calhoun, Jacob D.; Mayberry, Alanna; Ledezma, Melissa L.; Sams, Sharon B.; Orlicky, David J.; Donadi, Eduardo Antônio ; Haugen, Bryan R.; French, Jena D.
Assuntos: ANTINEOPLÁSICOS, MODELOS ANIMAIS, NEOPLASIAS DA TIREOIDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BERTOL, Bruna Cristina et al. Lenvatinib plus anti-PD-1 combination therapy for advanced cancers: defining mechanisms of resistance in an inducible transgenic model of thyroid cancer. Thyroid, v. 32, n. 2, p. 153-163, 2022Tradução . . Disponível em: https://doi.org/10.1089/thy.2021.0371. Acesso em: 02 nov. 2025.APA
Bertol, B. C., Bales, E. S., Calhoun, J. D., Mayberry, A., Ledezma, M. L., Sams, S. B., et al. (2022). Lenvatinib plus anti-PD-1 combination therapy for advanced cancers: defining mechanisms of resistance in an inducible transgenic model of thyroid cancer. Thyroid, 32( 2), 153-163. doi:10.1089/thy.2021.0371NLM
Bertol BC, Bales ES, Calhoun JD, Mayberry A, Ledezma ML, Sams SB, Orlicky DJ, Donadi EA, Haugen BR, French JD. Lenvatinib plus anti-PD-1 combination therapy for advanced cancers: defining mechanisms of resistance in an inducible transgenic model of thyroid cancer [Internet]. Thyroid. 2022 ; 32( 2): 153-163.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1089/thy.2021.0371Vancouver
Bertol BC, Bales ES, Calhoun JD, Mayberry A, Ledezma ML, Sams SB, Orlicky DJ, Donadi EA, Haugen BR, French JD. Lenvatinib plus anti-PD-1 combination therapy for advanced cancers: defining mechanisms of resistance in an inducible transgenic model of thyroid cancer [Internet]. Thyroid. 2022 ; 32( 2): 153-163.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1089/thy.2021.0371
